Indivior Pharmaceuticals, Inc 8-K, filed Nov 20, 2025
Indivior Pharmaceuticals, Inc. (INDV)
8-K
2025-11-20
For: 2025-11-20
View Original
Added on
April 10, 2026
About this 8-K
Indivior Pharmaceuticals, Inc filed this 8-K on November 20, 2025.
Items reported
- Item 1.02: Ended a material agreement
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: 804 -379-1040
| not applicable | ||
(Former name or former address, if changed since last report.) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.02 Termination of a Material Agreement
On November 20, 2025, Indivior, PLC (the “Registrant,” or the “Company,”) announced that it had satisfied its remaining obligations under that certain Resolution Agreement by and among Indivior Inc., Indivior PLC, the United States Attorney’s Office for the Western District of Virginia, and the United States Department of Justice’s Consumer Protection Branch made as of July 24, 2020 (the "Resolution Agreement"). As a result, the Resolution Agreement terminated on November 20, 2025.
Item 7.01 Regulation FD Disclosure.
On November 20, 2025, the Company issued a press release announcing the Company's payment of the remaining amounts owed to the DOJ. The press release is furnished as Exhibit 99.1 to this report and is incorporated herein.
Item 9.01 Exhibits
(d) Exhibits.
Exhibit No. | Description | |||||||
99.1 | Press release issued by Indivior PLC dated November 20, 2025. | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Indivior PLC | ||||||||
Date: November 20, 2025 | By: | /s/ Ryan Preblick | ||||||
| Name: Ryan Preblick | ||||||||
| Title: Chief Financial Officer | ||||||||
Exhibit 99.1
Indivior Concludes Legacy U.S. Department of Justice Matter
Richmond, VA, November 20, 2025 – Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ’s receipt of the payment, the resolution agreement with the DOJ will be terminated. The payment was funded with Indivior’s cash on hand.
“We are pleased to reach this important milestone that concludes the legacy DOJ matter,” said Joe Ciaffoni, Chief Executive Officer. “It removes a significant liability and simplifies our capital structure. We are committed to conducting business with integrity, maintaining a comprehensive compliance program and acting in a responsible and transparent manner.”
About Indivior
Indivior works to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease. Building on its portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.
For Further Information
Jason Thompson
VP, Investor Relations, Indivior PLC
+1 804-402-7123
Jason.thompson@indivior.com
Cassie France-Kelly
VP, Communications, Indivior PLC
+1 804-594-0836
Indiviormediacontacts@indivior.com
-ends-